Literature DB >> 8774205

Effect of oral estradiol on Lp(a) and other lipoproteins in postmenopausal women. A randomized, double-blind, placebo-controlled, crossover study.

C Haines1, T Chung, A Chang, J Masarei, B Tomlinson, E Wong.   

Abstract

BACKGROUND: Lp(a) lipoprotein level is an independent risk factor for premature coronary artery disease and cerebrovascular accident. Concentrations of this lipoprotein tend to increase after menopause.
OBJECTIVE: To determine whether oral estrogen was effective in lowering concentrations of Lp(a) lipoprotein in postmenopausal women.
METHODS: A double-blind, placebo-controlled, cross-over study was conducted during a 12-month period in 100 postmenopausal women who had undergone hysterectomy. They were randomized into two groups: group 1 received oral estradiol, 2 mg/d, for the first 6 months and placebo for the second, and group 2 received these treatments in the reverse order. After completion of the crossover study, the effect of prolonged administration of oral estradiol was examined by placing all patients on active treatment and repeating the lipoprotein measurements approximately 12 months later.
RESULTS: No significant differences were noted between the two groups at the commencement of the study (median concentration of Lp[a] lipoprotein, 10.78 mg/dL [range, 2.2 to 108.5 mg/dL] in group 1 and 12.74 mg/dL [range, 0.8 to 98.1 mg/dL] in group 2). Crossover analysis showed a 9.62% reduction in values of Lp(a) lipoprotein with estradiol treatment compared with placebo during 12 months of treatment (P < .001). With prolonged treatment, the median concentration of Lp(a) lipoprotein for those in group 1 decreased from 8.12 mg/dL (range, 1.05 to 57.4 mg/dL) to 5.77 mg/dL (range, 0.84 to 75.39 mg/dL) (P < .001). In group 2, the median concentration decreased from 8.19 mg/dL (range, 2.52 to 99.82 mg/dL) to 7.07 mg/dL (range, 0.70 to 48.79 mg/dL), but this difference was not significant (P = .63).
CONCLUSIONS: The results of this study confirm the beneficial effect of oral estradiol on the basic lipoprotein pattern and demonstrate that this treatment is effective in reducing concentrations of Lp(a) lipoprotein in postmenopausal women.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8774205

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  7 in total

Review 1.  Hormones and heart disease: what we thought, what we have learned, what we still need to know.

Authors:  Marian C Limacher
Journal:  Trans Am Clin Climatol Assoc       Date:  2002

Review 2.  Views from within and beyond: narratives of cardiac contractile dysfunction under senescence.

Authors:  Xiaoping Yang; Nair Sreejayan; Jun Ren
Journal:  Endocrine       Date:  2005-03       Impact factor: 3.633

3.  Cholesterol-fed ovariectomized monkeys are good animal models for human atherosclerosis of postmenopausal women.

Authors:  Ryuzo Torii; Masashi Shiomi; Takashi Ito; Satoshi Yamada; Yutaka Eguchi; Norimichi Ikeda
Journal:  Primates       Date:  2003-04-25       Impact factor: 2.163

Review 4.  Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis.

Authors:  Shelley R Salpeter; Judith M E Walsh; Elizabeth Greyber; Thomas M Ormiston; Edwin E Salpeter
Journal:  J Gen Intern Med       Date:  2004-07       Impact factor: 5.128

5.  Lipoprotein(a) and apolipoprotein(a) in polycystic ovary syndrome.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Wei Zhang; Adnan Abbuthalha; Parneet Kaur; Jasmeen Visla; Sidika Karakas; Lars Berglund
Journal:  Clin Endocrinol (Oxf)       Date:  2015-10-05       Impact factor: 3.478

Review 6.  Stroke in women: risk and prevention throughout the lifespan.

Authors:  Cheryl D Bushnell
Journal:  Neurol Clin       Date:  2008-11       Impact factor: 3.806

7.  The Effects of Menopause Hormone Therapy on Lipid Profile in Postmenopausal Women: A Systematic Review and Meta-Analysis.

Authors:  Guangning Nie; Xiaofei Yang; Yangyang Wang; Wanshi Liang; Xuewen Li; Qiyuan Luo; Hongyan Yang; Jian Liu; Jiajing Wang; Qinghua Guo; Qi Yu; Xuefang Liang
Journal:  Front Pharmacol       Date:  2022-04-12       Impact factor: 5.988

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.